Ege University, School of Medicine

Izmir 35100

0 studies enrolling now · 7 studies all time

What they study most

Cardiovascular Disease, Hemophilia A With Anti Factor VIII, Hemophilia A With Inhibitor, Idiopathic Pulmonary Fibrosis, Phenylketonuria (PKU), Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Severe Hemophilia A

Studies at this site

• Safety, Tolerability, and Efficacy Study of Valoctocogene Roxaparvovec in Hemophilia A With Active or Prior Inhibitors — Completed
• A Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Subcutaneous Emicizumab in Participants From Birth to 12 Months of Age With Hemophilia A Without Inhibitors — Running, not enrolling
• Clinical Study to Compare the Efficacy and Safety of Macitentan and Tadalafil Monotherapies With the Corresponding Fixed-dose Combination Therapy in Subjects With Pulmonary Arterial Hypertension (PAH) — Completed
• A Non-Interventional Interview Study of Phenylketonuria (PKU) Adults — Completed
• The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects — Stopped early
• Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study — Completed